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Abstract 
The lincosamide-resistant and macrolide-susceptible phenotype has not been 
described to date in Streptococcus pyogenes (group A Streptococcus; GAS). The 
aim of this study was to characterize a GAS isolate susceptible to macrolides but 
resistant to lincosamide, streptogramin A and pleuromutilin antibiotics (LSAP
phenotype). The antimicrobial susceptibility was tested by the microdilution broth 
method and the resistance phenotype by D-test. The GAS2887HUB isolate was 
subjected to whole-genome sequencing. The isolate showed a positive Gots’ test 
(clindamycin inactivation). WGS revealed the strain was ST10 and emm93 and had 
five resistance genes (lnu(B), ant(6)-Ia, aph(3')-III, tet(M), and dfrG). The tet(M) 
gene was located into a Tn916-like transposon. The lsa(E)lnu(B)-containing 
sequence (inserted downstream of the rumA gene) was formed by a 39.6-kb 
prophage, followed by a gene cluster encoding aminoglycoside-streptothricin 
resistance [ant(6)Iasat4aph(3')III] and lsa(E)lnu(B) genes. This structure was
not transferred by conjugation. In conclusion, we have described a new genetic 
element carrying a determinant of lincosamide resistance in a GAS. Further 
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molecular epidemiological surveys are needed to determine the prevalence of this 
mechanism of resistance in GAS. 
 





Streptococcus pyogenes (group A Streptococcus; GAS) is a major human 
pathogen that causes infections such as tonsillitis and skin and soft tissue infection 
[1]. Penicillins and cephalosporins are widely used to treat GAS infections due to 
the universal susceptibility of this bacterium to β-lactams. In cases of β-lactam 
allergy, macrolides or lincosamides are the recommended alternatives. Moreover, 
the addition of protein synthesis inhibitors, such as clindamycin, may effectively 
reduce the synthesis of virulence factors and improve patient outcomes [2].  
To date, two transferable mechanisms of macrolide and lincosamide 
resistance have been described in GAS (the ML phenotype). One involves 23S 
rRNA methylation (erm genes), responsible for resistance to macrolides, 
lincosamides and streptogramins B (the MLSB phenotype). The other involves 
active efflux (mef genes), conferring resistance to 14- and 15-membered 
macrolides (the so-called M phenotype) [3,4]. These genes are widespread in 
streptococci, mostly through the transfer of mobile genetic elements (MGEs) of the 
Tn916 family. Two additional phenotypes have been reported sporadically in other 
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streptococci: lincosamide inactivation by a nucleotidyltransferase (L phenotype, lnu 
genes); and resistance to lincosamide, streptogramin A and pleuromutilin 
antibiotics due to ribosomal protection (LSAP phenotype; lsa genes) [5,6]. The 
latter mechanism, also carried by MGEs, has been described in several human and 
animal streptococcal species [7–12], including one S. pyogenes isolate (erm(B) 
together with lsa(C); MLSB phenotype) [13]. 
In this study we describe, to the best of our knowledge, the first S. pyogenes 
isolate with an LSAP phenotype due to the presence of lsa(E) and lnu(B) genes. 
Moreover, we show that the genetic element carrying these genes was inserted 
into the S. pyogenes chromosome with a defective prophage similar to those 
recovered from swine pathogens. 
 
2. Materials and methods 
2.1 Bacterial strain and antibiotic susceptibility testing 
A S. pyogenes exhibiting a LSAP phenotype (GAS2887HUB) was obtained from a 
wound sample of a 77-year-old woman with cellulitis who was attended in the 
emergency department in September 2009. She consulted for a fever (39°C), 
headache, vomits and a confusional state. The physical examination revealed a 
pretibial leg ulcer was observed with signs of infection and cellulitis. Antipyretic and 
amoxicillin-clavulanic acid therapy was started after collecting blood cultures and 
wound samples. The patient presented good evolution after a 15-hour observation 
period and was discharged. After two weeks of amoxicillin-clavulanic treatment and 
one month of reepithelialisation therapy the wound resolved.  
5 
 
The antimicrobial susceptibility was tested by the broth microdilution 
reference method following the EUCAST recommendations. For antibiotics lacking 
recommendations, the Antibiogram Commitee of the French Society for 
Microbiology breakpoints were used (CA-SFM: www.sfm-microbiologie.org/). The 
ML phenotype was assessed by the D-test disk-diffusion method [3]. The following 
antimicrobials were tested: ampicillin, penicillin, cefotaxime, erythromycin, 
azithromycin, spiramycin, clindamycin, lincomycin, pristinamycin, quinupristin, 
dalfopristin, quinupristin-dalfopristin, tiamulin, tetracycline, chloramphenicol, 
ciprofloxacin, trimethoprim/sulfamethoxazole, amikacin, gentamicin, kanamycin, 
streptomycin and tobramycin. Lincosamide inactivation was screened using Gots’ 
test, as previously described [14]. 
 
2.2 WGS analysis 
Genomic DNA was extracted using a QIAamp DNA Mini Kit (Qiagen), quantified 
with a QuantiFluor dsDNA System (Promega Corporation, US) and was then 
adjusted to 0.2 ng/µL. Genome was sequenced using a 150 bp paired-end read 
protocol (NexteraXT kit and MiSeq, Illumina, US) at Macrogen, Inc. (Seoul, Rep. of 
Korea) .The quality of the sequencing was assessed with FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Afterwards, reads 
were trimmed, duplicated reads removed and errors corrected. Finally, they were 
assembled with Geneious 9.1.7 (Biomatters, New Zealand). 
The emm-type and MLST were deduced using the emm CDC databases for 
WGS (https://www2a.cdc.gov/ncidod/biotech/strepblast.asp; 
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https://pubmlst.org/spyogenes/). Additional sequence analysis was performed 
using different available online tools (ResFinder 3.0, ICEberg and Phaster) to 
explore the presence of acquired resistance mechanisms and different MGEs, such 
as integrative conjugative elements and prophages. The genetic environment of
lsa(E)lnu(B) was studied through comparison with previously described 
sequences present in public databases. For the putative prophage sequences 
predicted by Phaster, further characterisation was achieved using BlastX.
Comparisons between GAS2887HUB, sequences found to be similar based on 
nucleotide sequence alignments, and lsa(E)lnu(B) structures previously described 
in streptococci were displayed using Easyfig program.
2.3 Mating experiments 
S. pyogenes GAS3493HUB and S. agalactiae GBS4777HUB (rifampin-resistant 
MIC: 32 mg/L and clindamycin susceptible) were used as recipient strains for 
conjugation experiments performed on membrane filter, as described [15].
Transconjugants were selected using blood agar plates containing 20mg/L of
rifampicin and 4mg/L of clindamycin. Mating experiments were repeated three 
times.
3. Results and Discussion
3.1 Antibiotic resistance genes, susceptibility testing and molecular typing. 
The GAS2887HUB isolate was resistant to clindamycin, lincomycin, dalfopristin, 
tiamulin, tetracycline, amikacin, kanamycin, streptomycin and 
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trimethoprim/sulfamethoxazole, but it was susceptible to the remaining antibiotics 
tested (Supplementary material Table S1). Gots’ test was positive, proving 
lincosamide inactivation, whereas the D-test failed to reveal either synergy or 
induction events. Consistent with this, the analysis of acquired genes for antibiotic 
resistance (ResFinder 3.0) demonstrated the presence of lnu(B), ant(6)-Ia, aph(3')-
III, tet(M) and dfrG. The lsa(E) was not detected because it is not included in the 
ResFinder database. Besides this, the GAS2887HUB strain harboured a Tn916 
element [tet(M) gene], two prophage-like sequences (P1 and P2) and a partly 
deleted prophage (P3) (Supplementary material Fig. S1).  
The GAS2887HUB strain was emm93 and the sequence type was ST10, a 
rare association. In fact, this was the unique isolate with emm93 among nearly 500 
GAS collected over a twenty-year period. Furthermore, the GAS MLST database 
contains only 14 ST10 isolates, of which only 3 contain emm93 (2 isolates from 
India and 1 from Egypt). However, clindamycin susceptibility was not reported for 
any of these isolates, which meant that we could not clarify the putative clonal 
association of these resistance mechanisms, as with other resistance mechanisms 
in GAS [3]. 
 
3.2 WGS analysis: Genetic context of lsa(E)-lnu(B) genes 
To the best of our knowledge, the genetic environment of lsa(E)lnu(B) genes in 
our strain was different to that previously reported [7,8,13,16,17]. The lsa(E)lnu(B) 
genes resided together with the 39.6 kb P2 that was inserted downstream of the 
rumA gene (Fig. 1A). This sequence was formed by a 39.6 kb prophage, followed 
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by an aminoglycoside-streptothricin-resistance cluster [ant(6)Iasat4aph(3')III] 
and the lsa(E)lnu(B) genes. The extremes of this composite structure were highly
similar to the Streptococcus porci DSM 23759 prophage (67%100% identity,
average 85.8%, Acc. No. AUIP01000001, positions 157586) and to the 
lsa(E)lnu(B) genes (99.7% identity, Acc. No AUIP01000004, positions 
26907146). Moreover, the GAS2887HUB sequence containing from 
ant(6)Iasat4aph(3')III to lsa(E)lnu(B) was found in a different arrangement in 
Erysipelothrix rhusiopathiae Ery-11 [16] (Acc. No. KP339868, 99.1% identity, 
positions 1162217508; 99.9% identity, positions 48689307). The 
ant(6)Iasat4aph(3')III cluster shared 98.1% identity with the S. suis TZ080501 
genome (Acc. No. KX077897, positions 5129656201) (Fig. 1B). 
Among streptococci (Fig 1C), the MGE harbouring lsa(E)lnu(B) genes was
first reported in a S. agalactiae structure (SGB76) also containing a multidrug 
resistance cluster (aadEaptspw) [8]. This combination was also described with 
different arrangement in S.suis [17,18]. A second lsa(E)lnu(B)-containing element 
was described in a human S. agalactiae isolate (Fig 1C; 20162235) [7]. Beside 
this, the lnu(B) gene have been also found in streptococci and staphylococci with L 
and LSAP phenotypes isolated from animals and some food products [18],
indicating that some streptococci serve as a reservoir for antimicrobial resistance 
genes [17]. When comparing the characterized structures harbouring lsa(E)lnu(B) 
genes with GAS2887HUB (Fig. 1C), three findings were notable [8,16,18,19]. First, 
the orf4orf5lsa(E)lnu(B) structure was highly conserved (95% identity) among 
them. Second, in the previously described streptococcal structures, the 
9 
lsa(E)lnu(B) genes went together with a multidrug resistance cluster 
(aadEaptspw). Third, the aminoglycoside-streptothricin resistance cluster 
[ant(6)Iasat4aph(3')III] detected in our strain (GAS2887HUB) was found in a 
different arrangement in E. rhusiopathiae. 
The presence of a prophage highly similar to the one previously found in 
animal isolates of S. porci DSM 23759 [19], and E. rhusiopathiae [16,20], could 
suggest a putative animal source for this element. It is likely that the widespread 
use of lincosamides to treat (or prevent) infections in animals could have favoured 
the selection and spread of such mechanisms of resistance. In our strain, the 
genomic island located downstream of the defective prophage, which contains the 
ant(6)Iasat4aph(3')IIIcluster and lsa(E)lnu(B) resistance genes, could be a 
disrupted integrative mobilizable element. Nonetheless, it contains integration- and 
excision-like genes and one putative insertion sequence, but no genes required for 
MGE conjugation. However, no transconjugants were obtained after mating 
experiments. 
Clindamycin is frequently used, combined with a β-lactam, for the treatment 
of severe skin and soft tissue infections as prevents the ribosomal synthesis of
virulence factors. Furthermore, the WHO has included lincosamides and 
streptogramins in the list of critically important antimicrobials for the human 
medicine. To date clindamycin-resistance in GAS has been associated to erm 
genes responsible of the MLSB phenotype. The description of this new genomic 
island encoding lincosamide-resistance in macrolide-susceptible GAS is a cause of
concern and deserves surveillance of this rare resistance mechanism that could be 
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underestimated if clindamycin is not routinely tested. Moreover, lnu(B)-lsa(E) 
confers resistance to pleuromutilinas. Among them, lefamulin  is one of the eleven 
phase III antimicrobials included in the WHO 2017 priority list for antibacterial 
agents. 
 
4. Concluding remarks 
In conclusion, we have described a genomic island conferring LSAP 
phenotype in a GAS similar to those found in S. porci and E. rhusiopahiae. In vitro 
mobilization of this element by conjugation was not achieved. The presence of a 
lincosamide inactivation gene precludes the use of lincosamides in the treatment of 
severe GAS infections from this pathogen. Further studies are needed to 
understand if this mechanism of resistance is spread among GAS. 
 
Nucleotide sequence accession number 
Sequence data were deposited in the European nucleotide archive under the 
accession number ERS2881644. 
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Fig. 1. Schematic and comparative of the sequence containing lsa(E)lnu(B). 
A) Comparison of GAS2887HUB to the M1 GAS strain (reference GAS genome: 
Acc. No. NC_002737 positions 10805181152718) showing the insertion of the 
sequence containing lsa(E)lnu(B) genes together with the prophage 39.6 kb P2 
downstream of rumA (23S rRNA (uracil-5)-methyltransferase). The purple-gradated 
regions show 64%100% sequence identity, and the red line highlights the part of 
the GAS2887HUB sequence shown in more detail in Fig. 1B. B) Representation of 
the sequence containing lsa(E)lnu(B) genes together with the prophage 39.6 kb 
P2, showing the relatedness of the prophage sequence and lsa(E)lnu(B) genes 
with S. porci DSM 23759 [19] genome (Acc. No. AUIP01000001 positions 157586 
and Acc. No. AUIP01000004 positions 18831), the different of arrangement of the 
ant(6)Iasat4aph(3')III cluster and lsa(E)lnu(B) genes in E. rhusiopathiae Ery-11 
[16] (Acc. No. KP339868; positions 1162217508 and 48689307) and the 
presence of the ant(6)Iasat4aph(3')III cluster in S. suis TZ080501 [17] (Acc. No. 
KX077897 positions 4680368299). The yellow-to-blue-shaded regions show 
67%100% sequence identity. The green line emphasises the GAS2887HUB 
sequence shown in more detail in Fig. 1C. C) Distribution of the lsa(E)lnu(B) 
genes, the ant(6)Iasat4aph(3')III cluster and the aadEaptspw cluster among 
the previously described structures in streptococci containing lsa(E)lnu(B) genes 
[ICESsuNC28 of S. suis A7 [18] (Acc. No. KU2115704); S. porci DSM23759; S. 
agalactiae SGB76 [8] (Acc. No. KF772204); S. agalactiae 20162235 (SRA number 
SAMN06032954) [13] and E. rhusiopathiae Ery-11. There is a different 
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arrangement to that found in GAS2887HUB. The grey regions indicate that there is 
up to 95% sequence identity. 
 
